Our latest episode of the Investing Matters Podcast, featuring Janet Mui, award-winning investment industry commentator, has just been released. Listen here.
Correct. Sng share purchases now are advantaged and proven as being under fair value "Beyond Reasonable Doubt".
"Jeffrey Archer demonstrated his excellent grasp of share dealing in his 1987 play, Beyond Reasonable Doubt, where the main character, Sir David Metcalfe, makes investments thanks to "advice from an old friend" about a takeover bid.
Lord Archer can hardly have guessed that, seven years after his play packed the Queen's Theatre, in the West End, he would find himself embroiled in a share dealing affair."
Correct. This does not preclude results coming at Any Time. In Brookes husbands. Defense, if this were challenged in any way as insider trading, I would argue that there is such a massive amount of public domain knowledge out of the bag now indicating a positive clinical trial outcome and launch 95% probable that it became irresistible to buy the stock as an outside investor. The company itself has leaked a SOFT RNS in phase 3 outcome via in its own strategic actions and news releases. SO this investor will not be going to jail and has legitimate grounds to trade
That's a bit cheeky, knowing the C suite have seen the outcome! She must be party to news planning and see all the commerial infrastructure being built. More smoke, they think they can get away with it as its such a small investment
I tend to agree Justdeezerts. Bags of future growth but 2021 was the bum year since 2020 was bigger than normal due to covid and over stocking fear from end customers then getting unwound in 21. Nothing we didn't already know in my opinion. But moreover, JS has been unusually bullish in his language ALL over the RNS which speaks volumes to me as he doesn't often give away future outlook specifics. Clear there is lots of value uplift here for a medium term investors. His quote: "have already created substantial progress towards market expectations for 2022." He's saying that the end year 22 revenue forecast is largely de-risked since customers have committed to reformulate and can't really back out. Eg great growth as new cleaning customers come online 100% etc and new applications they are working on to diversify. I'm still very relaxed about holding here for bigger returns as the downside risk in this stock is low and it has intent to diversify strongly in coming years.
This is potentially big for us and as key support for future pandemic planning/stockpiling.... any one know a good agnostic product that can be toll out-license manufactured at scale with a very very fat royalty agreement to the originator?
So its a bit of a sanity check on patient understanding of their hospital release questionnaires for either the long covid part of the trial observation or in the latter part of the recovery process at home?
I know we have no RNS clinical data yet but surely all of this give away advertising jobs stuff in the 'public domain' cannot be totally extraneous to our Phase 3 expectations??? RM & Co information releases sort of inside information / insight on the quality of the data or am I barking mad? I did take the top up like many other in last few days but thinking more may be needed tomorrow!
I think that this pesky "virus" and all the "mutants" yet to be born from within our massive global human reservoir (not to mention cross infection and circulation risks to/from pets / farm animals / birds etc) has more "stealth, speed and agility" than man's combined efforts of pharma innovators, healthcare systems and Government in total, so your £1Bn value could easily be very materially understated...just watch and learn my friend over 2022-2025, the virus will be having more fun than you anticipate.
Dear MumboJumbo (apt name!) - you have completely missed the point with a very short sighted comment.... SNG001 is far bigger than any one COVID mutation or another, don't you get it yet? The other broader respiratory infectious disease therapy segments offer a massive market opportunity that dwarfs the current SP. Good luck buddy with your share buying plan! PS I've been in touch with 2 Big pharma colleagues in recent weeks and they tell me there is "watch-list" interest on P3 results, so that may help you in your little investment decision. :-)
My view is that because the INF anti-viral reaction pathway is impaired in Covid 19 infections, then the virus is allowed to "over replicate" and infect a far greater numbers of cells in many organs. Then, the other arsenal of human innate and adaptive immune components go into real over-drive, killing many more infected human cells than necessary and creating severe damage in the worst case in affected organs . I think this is the Long Covid effect. So I do think SNG001 will prevent progress to Long Covid (but not after its happened) and once proven will act as another significant turbo charger to the SNG001 franchise and SP trigger.
Excellent point Tony (assuming SNG001 P3 results are good or stellar). I believe many of us here were quietly thinking the exact same point in the background - SNG001 may prove to have massive "market disruption" potential since a decent proportion of people may not in future want to continue to have vaccine boosters+v4+v5+v6 or even take new variant protection vaccines as long as there is a good safety net reducing threat of severe hospitalised illness & death risk with SNG001. Personal Freedom and feeling of Wellbeing is a vote winner for Governments if they merchandise the concept with their healthcare strategy using our platform technology.
Docdaneeka - you seem to pounce aggressively to counter my every breath, word and view on this thread. "we won’t need any endorsement from JVT"....utter self serving rubbish! How is that conclusion supportable in any stretch of the imagination given that this stock is so under a bushel that hardly any stock investors in the USA know SNG even exists right now? Rightly or wrongly you are discouraging alternative thinking and possible strategic launch connections on this BB. Your comments about JVT is based on the fact you clearly mistrust or dislike him intensely. Thats it IMV. However, and its a BIG HOWEVER - JVT is already a MASSIVE HOUSEHOLD NAME in infectious diseases in the UK, whether you like him or not so for me if SNG and Soton Univ are surfing his market access waves (using him and his significant market authority) to get their impactful marketing message across to the masses then so be it....watch and maybe learn how this well orchestrated P3/pre-launch announcement may play out. If you were right all the time you would not be on this thread as you would be so rich from trading stocks years ago you would have your feet up drinking G&Ts on your own desert island beach somewhere idyllic.
Monday is "Big Bang" RNS and global breaking news day for SNG001....J Van-Tam on site in Soton Univ as endorsement of the technology advancement and excellent UK scientific breakthrough for improved treatment options for hospitalised patients with severe respiratory viral disease....gives SNG and JVT massive synergistic 'halo' effect to both parties.
Dear Oakleaf - thanks for raising my awareness of this online webinar - I'm now registered - yes very very interesting timing I agree with you. Here is my submitted question below and the same thrust of many messages I sent to UK Government & Kate Bingham Leader of the UK Vaccines Taskforce when Covid all kicked off:
Question submitted to JVT:
Regarding the COVID pandemic, with the benefit of hindsight, does the speaker agree that there is a highly important role for large cohort “Real World Evidence (RWE) studies”, that are rapidly expedited, and volunteer driven, within regulatory ‘lite’ clinical frameworks, to inform evidence of broad efficacy and safety benefits for drug assets in post-phase II (such as Soton Biotech, Synairgen’s SNG001 that exhibited a very clean safety profile and has existing clinical uses in other delivery forms)? This would remove the blockage of elongated and overly onerous regulated clinical trials processes for standard pharma assets, assuming presence of keen volunteers that legally agree to any treatment risk. If not, where would he draw the line of % death rate threshold of any new emerging infection variants, before he would recommend RWE methods as the way forwards to more rapidly introduce effective medicines and perhaps save countless lives globally?